Liminatus Pharma (LIMN) vs Xenetic Biosciences (XBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Xenetic Biosciences is the larger company by market cap ($5.0 million vs $5.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LIMN | XBIO |
|---|---|---|
| Share price | $3.69 | $2.12 |
| Market cap | $4.96M | $4.97M |
| 1-day change | -4.65% | -4.07% |
| EPS (TTM) | $-23.50 | $-1.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $141.50 | $8.87 |
| 52-week low | $3.29 | $1.87 |
| Distance from 52-week high | -97.39% | -76.10% |
| Average volume | 453.28K | 87.31K |
| Shares outstanding | 1.34M | 2.34M |
| Employees | 1 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Liminatus Pharma
LIMN stock →Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Healthcare · Biotechnology · 1 employees
About Xenetic Biosciences
XBIO stock →Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance.
Healthcare · Biotechnology · 2 employees
LIMN vs XBIO FAQ
Which is bigger, Liminatus Pharma or Xenetic Biosciences?
Xenetic Biosciences (XBIO) is larger, with a market capitalization of $4.97M compared with $4.96M for Liminatus Pharma (LIMN).
Are Liminatus Pharma and Xenetic Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.